S58 Metabolic and Therapeutic Aspects of Growth Hormone: Uses, Abuses, and Novel Therapeutics

Program: Symposia
Clinical Session
Sunday, April 3, 2016: 4:45 PM-6:15 PM
Room 210 (BCEC)
Chair:
Andrew R Hoffman, MD, VA Palo Alto Hlth Care System, Palo Alto, CA

Disclosures:
ARH: Principal Investigator, Teva, Consultant, AMBRX, Consultant, Versartis.
4:45 PM
Whitney W Woodmansee, M.D., Divison of Endocrine, Diabetes and Hypertension, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Disclosures:
WWW: Other activities, please specify:, Eli Lilly & Company, Investigator, Novo Nordisk, Investigator, Ipsen, Investigator, Versartis.
5:15 PM
Larry D Bowers, PhD, United States Anti-Doping Agency, Colorado Springs, CO
Nothing to Disclose: LDB
5:45 PM
Christian J Strasburger, MD, Endocrinology, Diabetes and Nutritional Medicine, Charité-Universitätsmedizin, Berlin, Germany
Disclosures:
CJS: , Modigentech /Prolor, Consultant, Versartis, Consultant, NovoNordisk, Consultant, Sandoz, former HypoCCS advisory board member, Eli Lilly.
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire